Francois Nader, MD, is a leading value builder in the biotech industry. He was President, Chief Executive Officer and a member of the Board of Directors of NPS Pharma from 2008 to 2015, when the company was acquired by Shire for $5.3 Billion. During his tenure as CEO Dr. Nader transformed NPS Pharma into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases. He was recognized as the Ernst and Young National Life Science Entrepreneur of the Year® in 2013. Dr. Nader currently serves as chairman of the board of directors of Acceleron Pharma Inc. (XLRN) and board director of several biopharma companies, including Baxalta Inc. (BXLT) and Clementia Pharmaceuticals, Inc.
Dr. Nader is a 30-year veteran of the healthcare industry. Before NPS, he was a venture partner at Care Capital. Prior to that, he served on the North America Leadership Team of Aventis and its predecessor companies holding a number of executive positions including senior vice-president, integrated healthcare markets and North America medical and regulatory affairs. Previously, he led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc.
Dr. Nader is also a leader in significant industry and business organizations. He is a Board member of the New Jersey Chamber of Commerce, and sits on the Advisory Board of the Open Future Institute. He is the immediate past chairman of BioNJ, New Jersey’s biotechnology trade organization and has served on the board of the Biotechnology Industry Organization (BIO), the national industry body.
Dr. Nader earned his French Doctorate in Medicine from St. Joseph University in Lebanon and his Physician Executive MBA from the University of Tennessee.